Overview
Interstitial lung disease specific to infancy (also referred to as childhood interstitial lung disease of infancy or chILD specific to infancy) encompasses a group of rare diffuse lung disorders that present exclusively or predominantly during the first years of life. These conditions primarily affect the lung parenchyma — the delicate tissue and air sacs (alveoli) responsible for gas exchange — leading to impaired oxygenation. The group includes several distinct entities such as neuroendocrine cell hyperplasia of infancy (NEHI), pulmonary interstitial glycogenosis (PIG), surfactant dysfunction disorders (caused by mutations in genes such as SFTPB, SFTPC, ABCA3, and NKX2-1), and developmental abnormalities including alveolar capillary dysplasia and acinar dysplasia. Key symptoms include tachypnea (rapid breathing), respiratory distress, hypoxemia (low blood oxygen levels), failure to thrive, persistent cough, and retractions (visible pulling in of the chest wall during breathing). Crackles may be heard on lung auscultation. Symptoms typically manifest in the neonatal or early infantile period, though the severity and progression vary considerably depending on the specific underlying diagnosis. Some forms, such as NEHI, tend to have a more favorable prognosis with gradual improvement over time, while surfactant dysfunction disorders can be severe and life-threatening. Treatment is largely supportive and may include supplemental oxygen therapy, nutritional support, and mechanical ventilation in severe cases. Systemic corticosteroids and hydroxychloroquine have been used in some subtypes, though evidence for their efficacy remains limited. Lung transplantation may be considered in the most severe, progressive forms that are refractory to medical management. Genetic testing and lung biopsy are important diagnostic tools. Management is best coordinated through multidisciplinary teams at specialized pediatric pulmonology centers.
Also known as:
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Interstitial lung disease specific to infancy.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Interstitial lung disease specific to infancy at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Interstitial lung disease specific to infancy.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Interstitial lung disease specific to infancy.
Community
No community posts yet. Be the first to share your experience with Interstitial lung disease specific to infancy.
Start the conversation →Latest news about Interstitial lung disease specific to infancy
No recent news articles for Interstitial lung disease specific to infancy.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Interstitial lung disease specific to infancy
What is Interstitial lung disease specific to infancy?
Interstitial lung disease specific to infancy (also referred to as childhood interstitial lung disease of infancy or chILD specific to infancy) encompasses a group of rare diffuse lung disorders that present exclusively or predominantly during the first years of life. These conditions primarily affect the lung parenchyma — the delicate tissue and air sacs (alveoli) responsible for gas exchange — leading to impaired oxygenation. The group includes several distinct entities such as neuroendocrine cell hyperplasia of infancy (NEHI), pulmonary interstitial glycogenosis (PIG), surfactant dysfunctio
At what age does Interstitial lung disease specific to infancy typically begin?
Typical onset of Interstitial lung disease specific to infancy is neonatal. Age of onset can vary across affected individuals.